

Derivation of lead substance for colorectal cancer treatment of Repebody-drug conjugate with EGFR overexpression tumor-specific selective effect

ProEn Therapeutics Inc.



ONCOLOGY	Lead
Product Type	Repebody-drug conjugate(RDC)
Indication	Solid cancers that overexpress EGFR, especially metastatic colorectal cancer
Target	EGFR-overexpressing tumor cells compared to normal cells
MoA(Mechanism of Action)	Induction of tumor cell death by conjugation drug after highly selective binding of Repebody to EGFR, which is overexpressed and clustered on the surface of tumor cells
Competitiveness	Binding selectively to tumor cells overexpressing EGFR compared to normal cells due to the avidity effect - Drug efficacy against KRAS mutations - Low side effects to normal cells
Development Stage	Lead
Route of Administration	Intravenous(IV)